IMVT vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

IMVT

54.3
AI Score
VS
IMVT Wins

MRNA

35.1
AI Score

Investment Advisor Scores

IMVT

54score
Recommendation
HOLD

MRNA

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IMVT MRNA Winner
Net Income -153.22M -2.82B IMVT
Operating Income -512,549 -3.07B IMVT
ROE -20.8% -32.6% IMVT
ROA -18.0% -22.9% IMVT
Total Assets 852.49M 12.34B MRNA
Cash 797.80M 2.60B MRNA
Current Ratio 7.27 3.29 IMVT
Free Cash Flow -124.41M -2.06B IMVT

Relative Price Performance (Last 90 Days)

IMVT 1M: -23.9% · 3M: -27.9% MRNA 1M: +34.6% · 3M: +331.1%

Current Technical Phase

IMVT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.6%), weak momentum, RSI 29

RSI (14): 28.8 · Price: $28.38

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (58.0% over 20 days), RSI 69

RSI (14): 69.1 · Price: $245.81

Fundamentals Snapshot

Metric IMVT MRNA
Market Cap — —
Forward P/E -11.0 -51.1
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — -0.7%
Operating Margin 0.0% -5.6%
EPS -2.82 -7.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IMVT is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.